Status:
UNKNOWN
Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer
Lead Sponsor:
Shengjing Hospital
Conditions:
Breast Cancer
Eligibility:
FEMALE
18-70 years
Phase:
PHASE3
Brief Summary
Pfizer's innovative drug palbociclib (trade name: Ibrance®) got China National Drug Administration (CNDA) approval on July 31, 2018. Palbociclib combined with an aromatase inhibitor can be used to tre...
Detailed Description
Breast cancer is one of the most common cancers in women. Once advanced, it is usually not cured. Studies have shown that patients with advanced breast cancer have a median survival of 2-3 years. For ...
Eligibility Criteria
Inclusion
- Patients with histological and imaging findings-confirmed hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer;
- postmenopausal patients;
- eligible patients receiving one or more treatment strategies who are followed up in the center where they receive treatment;
- provision of written informed consent.
Exclusion
- Age \< 18 years;
- pregnant woman;
- participating in other clinical trials.
Key Trial Info
Start Date :
September 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2022
Estimated Enrollment :
420 Patients enrolled
Trial Details
Trial ID
NCT04047758
Start Date
September 1 2019
End Date
September 30 2022
Last Update
July 20 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, China
2
Liaoning Provincial People's Hospital
Shenyang, Liaoning, China
3
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China